ATE517926T1 - Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 - Google Patents

Antikörper zur hemmung der aktivität von mmp-2 und mmp-9

Info

Publication number
ATE517926T1
ATE517926T1 AT04725641T AT04725641T ATE517926T1 AT E517926 T1 ATE517926 T1 AT E517926T1 AT 04725641 T AT04725641 T AT 04725641T AT 04725641 T AT04725641 T AT 04725641T AT E517926 T1 ATE517926 T1 AT E517926T1
Authority
AT
Austria
Prior art keywords
mmp
activity
antibodies
inhibit
antibody
Prior art date
Application number
AT04725641T
Other languages
English (en)
Inventor
Irit Sagi
Tamar Danon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE517926T1 publication Critical patent/ATE517926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04725641T 2003-04-04 2004-04-04 Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 ATE517926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46000503P 2003-04-04 2003-04-04
PCT/IL2004/000308 WO2004087042A2 (en) 2003-04-04 2004-04-04 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
ATE517926T1 true ATE517926T1 (de) 2011-08-15

Family

ID=33131910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725641T ATE517926T1 (de) 2003-04-04 2004-04-04 Antikörper zur hemmung der aktivität von mmp-2 und mmp-9

Country Status (6)

Country Link
US (4) US7524938B2 (de)
EP (2) EP2330132B1 (de)
AT (1) ATE517926T1 (de)
DK (2) DK1610678T3 (de)
ES (2) ES2433440T3 (de)
WO (1) WO2004087042A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517926T1 (de) * 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
ES2524015T3 (es) 2005-12-30 2014-12-03 Dyax Corporation Proteínas de enlazamiento a la metaloproteinasa
CN101702906B (zh) * 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
EP2186894A4 (de) 2007-07-10 2010-10-20 Shionogi & Co Monoklonaler antikörper mit neutralisierender aktivität gegen mmp13
KR20100071972A (ko) * 2007-08-15 2010-06-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Ｍｍｐ-9의 조절인자 및 그의 용도
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2009079581A1 (en) * 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
AU2009221916A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
WO2010029352A1 (en) * 2008-09-09 2010-03-18 University Of East Anglia Treatment of fibrotic eye disorders using an mmp2 inhibitor
CN101559076B (zh) * 2009-05-27 2012-08-29 西北大学 抗肿瘤基质金属蛋白酶抑制剂
CA2787311C (en) 2010-01-27 2017-08-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
EP2608809B1 (de) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antikörper gegen matrix-metalloproteinase-9
WO2012056455A1 (en) 2010-10-28 2012-05-03 Yeda Research And Development Co. Ltd. Methods of generating antibodies to metalloenzymes
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
CA2861402C (en) 2012-01-30 2021-10-12 Guy Casy Stabilized aqueous antibody compositions
HK1204926A1 (en) 2012-02-29 2015-12-11 吉联亚生物科技有限公司 Antibodies to matrix metalloproteinase 9
EP3656861B1 (de) 2017-07-18 2025-07-23 Daiichi Sankyo Company, Limited Aktives mmp9-bindendes peptid
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
KR20250095278A (ko) * 2023-12-19 2025-06-26 주식회사 메디아크 포르피린-기반의 금속-유기 골격체를 포함하는 대식세포 분극화 유도용 조성물 및 이의 용도

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
AU3899193A (en) 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5800814A (en) 1994-04-22 1998-09-01 Oklahoma Medical Research Foundation Method for inhibition of breast tumor growth
AU2361295A (en) 1994-04-28 1995-11-29 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
US5629980A (en) * 1994-11-23 1997-05-13 Xerox Corporation System for controlling the distribution and use of digital works
PT757984E (pt) 1995-08-08 2003-02-28 Ono Pharmaceutical Co Derivados de acido hidroxamico uteis para inibir a gelatinase
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
PT871439E (pt) 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
WO1997049679A1 (en) 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP3673888B2 (ja) 1998-03-09 2005-07-20 独立行政法人科学技術振興機構 ポルフィリン類金属錯体の製造方法
CN1310716A (zh) 1998-07-30 2001-08-29 沃尼尔·朗伯公司 作为基质金属蛋白酶抑制剂的三环磺胺化合物及其衍生物
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003044058A2 (en) * 2001-11-23 2003-05-30 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
ATE517926T1 (de) * 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9

Also Published As

Publication number Publication date
US20090208510A1 (en) 2009-08-20
WO2004087042A3 (en) 2005-07-14
US20070172482A1 (en) 2007-07-26
EP1610678A4 (de) 2008-04-09
EP2330132A1 (de) 2011-06-08
US8841108B2 (en) 2014-09-23
ES2369498T3 (es) 2011-12-01
US20120003236A1 (en) 2012-01-05
EP1610678B1 (de) 2011-07-27
EP2330132B1 (de) 2013-08-14
DK1610678T3 (da) 2011-10-24
US20140370031A1 (en) 2014-12-18
WO2004087042A2 (en) 2004-10-14
EP1610678A2 (de) 2006-01-04
ES2433440T3 (es) 2013-12-11
DK2330132T3 (da) 2013-11-04
US7524938B2 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
ATE517926T1 (de) Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
DK1257584T4 (da) Humaniserede antistoffer, der sekvestrerer amyloid beta-peptid
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
ATE504315T1 (de) Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
ATE470676T1 (de) Anti-vegf-2 antikörper
ATE497783T1 (de) Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
DE602005015542D1 (de) Varianten der fc-region
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE60236965D1 (de) Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
DE60216939D1 (de) Verwendung von plasminogen zur heilung von zerbrochenen trommelfellen
EP1615946A4 (de) Proteolytische und kovalente antikörper
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
DE69839767D1 (de) Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties